|Prof. Lior Rosenberg M.D.||Co-Founder & Medical Director||398k||N/A||1946|
|Mr. Boaz Gur-Lavie CPA, M.B.A.||Chief Financial Officer||309k||N/A||1974|
|Mr. Yaron Meyer Adv.||Exec. VP, Gen. Counsel & Corp. Sec.||240k||N/A||1979|
|Dr. Ety Klinger||Chief R&D Officer||344k||N/A||1962|
|Mr. Ofer Gonen B.Sc.||Chief Exec. Officer||N/A||N/A||1973|
|Mr. Tzvi Palash B.Sc., M.Sc.||Chief Operating Officer||N/A||N/A||1957|
|Mr. Stephen T. Wills CPA, CPA, MST||Exec. Director||N/A||N/A||1957|
|Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc.||Chief Medical Officer||N/A||N/A||N/A|
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.